Skip to Content

Tbo-filgrastim Pregnancy and Breastfeeding Warnings

Tbo-filgrastim is also known as: Granix

Medically reviewed on February 14, 2017

Tbo-filgrastim Pregnancy Warnings

Use of tbo-filgrastim is not recommended unless the benefit outweighs the risk to the developing fetus.

US FDA pregnancy category: Not Assigned

Risk Summary: Limited published data on use during pregnancy are insufficient to inform a drug-associated risk.

Animal studies have revealed evidence of embryolethality and fetotoxicity at doses that produced maternal toxicity. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Tbo-filgrastim Breastfeeding Warnings

Other recombinant granulocyte colony stimulating factor (G-CSF) products are poorly secreted in breast milk and G-CSF is not orally absorbed by neonates.

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA.

References for breastfeeding information

  1. "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide